Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
Business Wire•16/11/2026•16:05 ET
0
Key Highlights
- ➤Gilead signed royalty-free obeldesivir licenses with three generic manufacturers.
- ➤Obeldesivir agreements cover 127 primarily low- and lower-middle-income countries.
- ➤EBO-PEP Phase 3 trial is evaluating obeldesivir as Ebola BVD prophylaxis.
- ➤Gilead expanded remdesivir licenses to include potential filovirus disease access.
- ➤Gilead donated more than 2,000 remdesivir vials to Kenya for investigational use.
Expert Statements
Jaime McCoy, Vice President, Gilead Patient Solutions, Gilead Sciences
“Responding to emerging infectious diseases, including Ebola virus disease, requires not only scientific innovation, but also early planning and collaboration to help ensure that effective medicines can reach the people who need them as quickly as possible”
Jaime McCoy, Vice President, Gilead Patient Solutions, Gilead Sciences
“These agreements reflect our commitment to preparing for future access while clinical research is ongoing, so that we are better positioned to respond if these investigational medicines demonstrate benefit and gain regulatory approval.”
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and Potential Regulatory Submissions -
Get started
Create a free account to read the full story.
